Monoamine oxidase inhibitor
| Monoamine oxidase inhibitor | |
|---|---|
| Drug class | |
| Class identifiers | |
| Synonyms | MAOI, RIMA |
| Use | Treatment of major depressive disorder, atypical depression, Parkinson's disease, and several other disorders |
| ATC code | N06AF |
| Mechanism of action | Enzyme inhibitor |
| Biological target | Monoamine oxidase enzymes: MAO-A and/or MAO-B |
| External links | |
| MeSH | D008996 |
| Legal status | |
| In Wikidata | |
Monoamine oxidase inhibitors (MAOIs) are a class of drugs that inhibit the activity of one or both monoamine oxidase enzymes: monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B). They are best known as effective antidepressants, especially for treatment-resistant depression and atypical depression. They are also used to treat panic disorder, social anxiety disorder, Parkinson's disease, and several other disorders.
Reversible inhibitors of monoamine oxidase A (RIMAs) are a subclass of MAOIs that selectively and reversibly inhibit the MAO-A enzyme. RIMAs are used clinically in the treatment of depression and dysthymia. Due to their reversibility, they are safer in single-drug overdose than the older, irreversible MAOIs, and weaker in increasing the monoamines important in depressive disorder. RIMAs have not gained widespread market share in the United States.